Long-term clinical and angiographic follow-up results of the dual-layer flow diverter device (FRED) for the treatment of intracranial aneurysms in a multicenter study

Basit Öğe Kaydı
dc.contributor.authorDinc, Hasan
dc.contributor.authorSaatci, Isil
dc.contributor.authorOguz, Sukru
dc.contributor.authorBaltacioglu, Feyyaz
dc.contributor.authorYildiz, Altan
dc.contributor.authorDonmez, Halil
dc.contributor.authorBelet, Umit
dc.date.accessioned2024-02-23T13:43:33Z
dc.date.available2024-02-23T13:43:33Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractPurpose Our aim was to determine the long-term safety and efficacy of the Flow Re-Direction Endoluminal Device (FRED) in this multicenter study with prospective design. Materials-method This study included 136 consecutive patients with 155 aneurysms treated between March 2013 and June 2016 in 10 centers. Twenty-two (16.2%) patients presented with rupture of the index aneurysm. Large/giant aneurysms comprised 1/3 of the cohort. Adjuvant coil use during the treatment was 15.5%. The effectiveness measure in the study was the percentage of aneurysms with stable occlusion at follow-up. Results Vascular imaging follow-up was performed at least once in 131/136 (96.3%) patients with 148/155 (95.5%) aneurysms up to 75 months (mean: 37.3 months; median: 36 months according to latest follow-up), and 102/155(65.8%) aneurysms in 90/136 (66.2%) patients had >= 24-month control. According to the latest controls, the overall stable occlusion rate was 91.9% (95% CI, 87.5 to 96.3%). Three out of 148 aneurysms with follow-up were retreated (2%, 95% CI 0.0 to 4.3%). Adverse events were noted in 19/136 (14%, 95% CI, 9 to 21%) patients with a morbidity of 1.5% (95% CI, 0.0 to 3.5%). Mortality was 1/136 (0.7%, 95% CI, 0.02 to 2.2%) and was unrelated to aneurysm treatment. In-stent stenosis (ISS) was detected in 10/131 of the patients with follow-up (7.6%, 95% CI; 3.1 to 12.2%), only one being symptomatic. No adverse events have occurred in any of the patients with follow-up after 24 months, except the one resulting from ISS. Conclusion In the treatment of cerebral aneurysms which were candidates for flow diversion technique, this study showed long-term efficacy of FRED with good safety and occlusion rates.en_US
dc.description.sponsorshipMicroVention Inc. (Aliso Viejo, CA, USA); Medtronic Inc. (Minneapolis, USA); Stryker (Neurovascular, Freemont, CA, USA)en_US
dc.description.sponsorshipFeyyaz Baltacioglu: Financial support for attending symposia and educational programs MicroVention Inc. (Aliso Viejo, CA, USA), Medtronic Inc. (Minneapolis, USA), and Stryker (Neurovascular, Freemont, CA, USA).en_US
dc.identifier.doi10.1007/s00234-020-02627-1
dc.identifier.endpage952en_US
dc.identifier.issn0028-3940
dc.identifier.issn1432-1920
dc.identifier.issue6en_US
dc.identifier.pmid33392735en_US
dc.identifier.scopus2-s2.0-85098655736en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage943en_US
dc.identifier.urihttps://doi.org/10.1007/s00234-020-02627-1
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10852
dc.identifier.volume63en_US
dc.identifier.wosWOS:000604485200005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofNeuroradiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCerebral Aneurysmen_US
dc.subjectFlow Diversionen_US
dc.subjectEndovascular Treatmenten_US
dc.subjectFlow Re-Direction Endoluminal Device? =? Freden_US
dc.titleLong-term clinical and angiographic follow-up results of the dual-layer flow diverter device (FRED) for the treatment of intracranial aneurysms in a multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu